Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains the leading cause of death globally and a significant contributor to rising healthcare expenses. According to the American Heart Association, direct and indirect costs of cardiovascular disease in the United States are projected to exceed $1.1 trillion by 2035. For employers and health plans, managing these costs is critical. Cardio Diagnostics' AI-powered solutions aim to address this challenge by enabling earlier detection of coronary heart disease risk through advanced genetic and epigenetic analysis.
The company's offerings include Epi+Gen CHD, a test that combines genetic and epigenetic biomarkers to assess risk of coronary heart disease; PrecisionCHD, which provides a more detailed risk assessment; and the HeartRisk population insights platform, which aggregates data to help organizations identify high-risk individuals and implement targeted interventions. By presenting at these benefits conferences, Cardio Diagnostics seeks to demonstrate how its technology can help reduce healthcare spending and improve employee health outcomes.
The conferences provide a platform for the company to connect with key decision-makers who influence health plan design and implementation. For benefits brokers and consultants, understanding the latest innovations in precision medicine is essential to offering clients cost-effective solutions. For union trustees and plan administrators, adopting such technologies could lead to better management of chronic disease within their populations.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. For more information about the full press release, visit https://ibn.fm/qFRHu.
